Cargando…

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease

Background: Previous studies have investigated associations between apolipoprotein E (APOE)-ɛ4 allele status and acetylcholinesterase inhibitor treatment response in patients with Alzheimer’s disease. The ability to draw definitive conclusions regarding the effect of APOE-ɛ4 genotype on treatment re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waring, Jeffrey F., Tang, Qi, Robieson, Weining Z., King, David P., Das, Ujjwal, Dubow, Jordan, Dutta, Sandeep, Marek, Gerard J., Gault, Laura M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923746/ https://www.ncbi.nlm.nih.gov/pubmed/26402762 http://dx.doi.org/10.3233/JAD-142589

Ejemplares similares

Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease
por: Fernandez, Hubert H, et al.
Publicado: (2016)

A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia
por: Gault, Laura M., et al.
Publicado: (2015)

APOE-ε4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease
por: Hou, Min, et al.
Publicado: (2021)

Transdermal donepezil on the treatment of Alzheimer’s disease
por: Sozio, Piera, et al.
Publicado: (2012)

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
por: Gault, Laura M., et al.
Publicado: (2016)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
por: Unzeta, Mercedes, et al.
Publicado: (2016)

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases
por: Alvarez, X. Anton, et al.
Publicado: (2016)

mTOR: Alzheimer's disease prevention for APOE4 carriers
por: Lin, Ai-Ling, et al.
Publicado: (2016)

Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers
por: Norwitz, Nicholas G., et al.
Publicado: (2021)

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
por: Pooladgar, Parham, et al.
Publicado: (2022)

Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease
por: Epstein, Michael, et al.
Publicado: (2016)

Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer’s Disease in Rat Model
por: Shehata, Mustafa K, et al.
Publicado: (2023)

THE COMPARISON OF DUAL TASK TIME AMONG APOE CARRIERS AGAINST NON-APOE CARRIERS IN AGING ADULTS
por: Diehl, Cody, et al.
Publicado: (2022)

Bioenergetic and inflammatory systemic phenotypes in Alzheimer’s disease APOE ε4‐carriers
por: Wilkins, Heather M., et al.
Publicado: (2021)

Platelet cytochrome oxidase and citrate synthase activities in APOE ε4 carrier and non-carrier Alzheimer's disease patients
por: Wilkins, Heather M., et al.
Publicado: (2017)

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
por: Cacabelos, Ramón
Publicado: (2007)

Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Hardy, Chris J. D., et al.
Publicado: (2017)

Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients
por: Yiannopoulou, Konstantina G., et al.
Publicado: (2019)

A Systems View of the Differences between APOE ε4 Carriers and Non-carriers in Alzheimer’s Disease
por: Jiang, Shan, et al.
Publicado: (2016)

Vascular Dysfunction Is Central to Alzheimer’s Disease Pathogenesis in APOE e4 Carriers
por: McCorkindale, Andrew N., et al.
Publicado: (2022)

Studies on Interaction of Buffalo Brain Cystatin with Donepezil: An Alzheimer's Drug
por: Amin, Fakhra, et al.
Publicado: (2013)

Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease
por: Hwang, Yun Tae, et al.
Publicado: (2018)

Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Campbell, Tom A., et al.
Publicado: (2018)

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
por: Chase, Thomas N., et al.
Publicado: (2017)

Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China
por: Liu, Mengyuan, et al.
Publicado: (2014)

Oscillatory hyperactivity and hyperconnectivity in young APOE-ɛ4 carriers and hypoconnectivity in Alzheimer’s disease
por: Koelewijn, Loes, et al.
Publicado: (2019)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
por: Zhang, Nan, et al.
Publicado: (2018)

Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy
por: Pachón-Angona, Irene, et al.
Publicado: (2019)

Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer’s disease
por: Al Harthi, Sitah, et al.
Publicado: (2019)

Donepezil improves vascular function in a mouse model of Alzheimer’s disease
por: Pellegrini, Carolina, et al.
Publicado: (2021)

Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia
por: Park, Kee Hyung, et al.
Publicado: (2021)

Modified reference based imputation and tipping point analysis in the presence of missing data due to COVID-19
por: Jin, Man, et al.
Publicado: (2021)

Donepezil plus memantine versus donepezil alone for treatment of concomitant Alzheimer’s disease and chronic obstructive pulmonary disease: a retrospective observational study
por: Cao, Yangyi, et al.
Publicado: (2020)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers
por: Tao, Qiushan, et al.
Publicado: (2018)

Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia
por: Yaowaluk, Thitipon, et al.
Publicado: (2019)

Delirium Associated with Donepezil in a Patient with Alzheimer's Disease: a Case Report
por: Mollazadeh-Moghaddam, Kamyar, et al.
Publicado: (2013)

Donepezil and life expectancy in Alzheimer’s disease: A retrospective analysis in the Tajiri Project
por: Meguro, Kenichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3u6kd410ho9ajrsh396dho0m0m